X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Unichem Lab with Strides Arcolab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs STRIDES SHASUN LTD - Comparison Results

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB STRIDES SHASUN LTD UNICHEM LAB/
STRIDES SHASUN LTD
 
P/E (TTM) x -62.7 41.4 - View Chart
P/BV x 0.7 1.0 68.2% View Chart
Dividend Yield % 2.4 1.0 250.4%  

Financials

 UNICHEM LAB   STRIDES SHASUN LTD
EQUITY SHARE DATA
    UNICHEM LAB
Mar-18
STRIDES SHASUN LTD
Mar-17
UNICHEM LAB/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs3821,275 30.0%   
Low Rs234918 25.5%   
Sales per share (Unadj.) Rs116.3389.6 29.9%  
Earnings per share (Unadj.) Rs-18.928.0 -67.7%  
Cash flow per share (Unadj.) Rs-11.748.9 -24.0%  
Dividends per share (Unadj.) Rs5.004.50 111.1%  
Dividend yield (eoy) %1.60.4 395.4%  
Book value per share (Unadj.) Rs381.0303.1 125.7%  
Shares outstanding (eoy) m70.3489.42 78.7%   
Bonus/Rights/Conversions BBESOP-  
Price / Sales ratio x2.62.8 94.1%   
Avg P/E ratio x-16.339.2 -41.5%  
P/CF ratio (eoy) x-26.222.4 -117.0%  
Price / Book Value ratio x0.83.6 22.4%  
Dividend payout %-26.416.1 -164.2%   
Avg Mkt Cap Rs m21,66898,036 22.1%   
No. of employees `0002.35.8 39.3%   
Total wages/salary Rs m2,0065,881 34.1%   
Avg. sales/employee Rs Th3,587.86,005.9 59.7%   
Avg. wages/employee Rs Th880.01,014.0 86.8%   
Avg. net profit/employee Rs Th-583.7431.2 -135.4%   
INCOME DATA
Net Sales Rs m8,18034,834 23.5%  
Other income Rs m6101,686 36.2%   
Total revenues Rs m8,79036,520 24.1%   
Gross profit Rs m-1,3206,428 -20.5%  
Depreciation Rs m5051,872 27.0%   
Interest Rs m802,269 3.5%   
Profit before tax Rs m-1,2953,973 -32.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m-24 -61.1%   
Extraordinary Inc (Exp) Rs m0-1,006 0.0%   
Tax Rs m33470 7.1%   
Profit after tax Rs m-1,3312,501 -53.2%  
Gross profit margin %-16.118.5 -87.5%  
Effective tax rate %-2.611.8 -21.8%   
Net profit margin %-16.37.2 -226.6%  
BALANCE SHEET DATA
Current assets Rs m23,31838,165 61.1%   
Current liabilities Rs m4,63530,402 15.2%   
Net working cap to sales %228.422.3 1,024.8%  
Current ratio x5.01.3 400.7%  
Inventory Days Days12277 157.4%  
Debtors Days Days121104 116.3%  
Net fixed assets Rs m8,16337,639 21.7%   
Share capital Rs m141894 15.7%   
"Free" reserves Rs m26,66026,210 101.7%   
Net worth Rs m26,80127,105 98.9%   
Long term debt Rs m316,377 0.0%   
Total assets Rs m31,89081,168 39.3%  
Interest coverage x-15.22.8 -551.5%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.30.4 59.8%   
Return on assets %-3.95.9 -66.7%  
Return on equity %-5.09.2 -53.8%  
Return on capital %-4.512.1 -37.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,35613,465 32.4%   
Fx outflow Rs m04,076 0.0%   
Net fx Rs m4,3569,389 46.4%   
CASH FLOW
From Operations Rs m-1,1232,881 -39.0%  
From Investments Rs m16,487-7,051 -233.8%  
From Financial Activity Rs m-8,8113,382 -260.5%  
Net Cashflow Rs m6,552-788 -831.9%  

Share Holding

Indian Promoters % 50.1 27.7 180.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 15.1 37.8 39.9%  
FIIs % 3.0 8.6 34.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 31.7 25.9 122.4%  
Shareholders   20,176 56,241 35.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   NOVARTIS  TORRENT PHARMA  FRESENIUS KABI ONCO.  STERLING BIOTECH  ASTRAZENECA PHARMA  

Compare UNICHEM LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Sell-Off; Sensex Slumps Over 530 Points(Closing)

Share markets in India continued their sell-off seen during the last week and ended the day deep in the red. All sectoral indices traded on a negative note.

Related Views on News

STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY19); Net Profit Down 1479.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, UNICHEM LAB has posted a net profit of Rs 207 m (down 1479.6% YoY). Sales on the other hand came in at Rs 2 bn (down 35.9% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Sep 24, 2018 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB - NATCO PHARMA COMPARISON

COMPARE UNICHEM LAB WITH

MARKET STATS